TargetMol

Ifosfamide

Product Code:
 
TAR-T1055
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1055-100mg100mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1055-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1055-200mg200mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1055-500mg500mg£147.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication. Ifosfamide is a synthetic analog of the nitrogen mustard cyclophosphamide with antineoplastic activity. This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes.
CAS:
3778-73-2
Formula:
C7H15Cl2N2O2P
Molecular Weight:
261.08
Pathway:
DNA Damage/DNA Repair; Cell Cycle/Checkpoint
Purity:
0.9986
SMILES:
ClCCNP1(=O)OCCCN1CCCl
Target:
DNA Alkylator/Crosslinker; DNA/RNA Synthesis

References

1. Chang TK, et al. Cancer Res, 1997, 57(10), 1946-1954. 2. Dechant KL, et al. Drugs, 1991, 42(3), 428-467. 3. Chen L, et al. Cancer Res, 1996, 56(6), 1331-1340. 4. Heymann D, et al. Bone, 2005, 37(1), 74-86. 5. Ribeiro RA, et al. J Urol, 2002, 167(5), 2229-2234. 6. Vredenburg G, et al. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. Toxicol Lett. 2015 Jan 5;232(1):182-92. 7. Helal M. Prenatal effects of transplacental exposure to ifosfamide in rats. Biotech Histochem. 2016 Jul;91(5):357-68.